BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//pretalx//sciencenext.org//ifos2026//J9ZWHS
BEGIN:VTIMEZONE
TZID:EET
BEGIN:STANDARD
DTSTART:20001029T030000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10;UNTIL=20061029T000000Z
TZNAME:EET
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
END:STANDARD
BEGIN:STANDARD
DTSTART:20071028T050000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10;UNTIL=20141026T020000Z
TZNAME:EET
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
END:STANDARD
BEGIN:STANDARD
DTSTART:20151108T050000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=11;UNTIL=20151108T020000Z
TZNAME:EET
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
END:STANDARD
BEGIN:STANDARD
DTSTART:20160907T010000
RRULE:FREQ=YEARLY;BYDAY=1WE;BYMONTH=9
TZNAME:+03
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20000326T020000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20060326T000000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20070325T040000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20100328T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20110328T040000
RRULE:FREQ=YEARLY;BYDAY=4MO;BYMONTH=3;UNTIL=20110328T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20120325T040000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20130331T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20140331T040000
RRULE:FREQ=YEARLY;BYDAY=5MO;BYMONTH=3;UNTIL=20140331T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20150329T040000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20160327T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:pretalx-ifos2026-MJDF9E@sciencenext.org
DTSTART;TZID=EET:20260911T090000
DTEND;TZID=EET:20260911T100000
DESCRIPTION:<p style="margin-left: 0px!important\;">The goal of this round-
 table is to discuss several&nbsp\; advances in the understanding of this c
 ondition with a special emphasis on new trends in&nbsp\; emergent therapie
 s. For such\, we brought together a group of experts to discuss the experi
 ence in the manage of olfactory disorders in patients post-covid and no co
 vid that no improve with traditionally described treatments. 1. Intranasal
  insulin and prf will be used in post-covid patients. 2. Virtual reality a
 nd artificial intelligence .Why do we do it? 3. Olfactory disorders post.i
 nfectious .UP to day. 4. Biologics use in the patients with RNSwpolyps and
  olfactory disorders <a target="_blank" rel="noopener noreferrer nofollow"
  href="http://5.Is">5.Is</a> phototherapy a beneficial option for patients
  with post-covid olfactory disorders.</p>
DTSTAMP:20260813T210612Z
LOCATION:Rhinology 5 + Allergy (ICC - B2 level YILDIZ 1)
SUMMARY:NEW TRENDS IN DIAGNOSTIC AND TREATMENT OF OLFACTORY DISORDERS - Ros
 alinda Pieruzzini\, Adriana Izquierdo\, Patricia Portillo\, Adelaida Bock
URL:https://sciencenext.org/ifos2026/talk/MJDF9E/
END:VEVENT
END:VCALENDAR
